Share on StockTwits
 

Acorda Therapeutics (NASDAQ:ACOR) announced its earnings results on Wednesday. The company reported $0.32 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.18 by $0.14, Stock Ratings Network reports. The company had revenue of $92.59 million for the quarter, compared to the consensus estimate of $89.96 million. During the same quarter last year, the company posted $0.24 earnings per share. Acorda Therapeutics’s revenue was up 13.6% compared to the same quarter last year.

Shares of Acorda Therapeutics (NASDAQ:ACOR) opened at 34.68 on Wednesday. Acorda Therapeutics has a 1-year low of $27.51 and a 1-year high of $40.87. The stock’s 50-day moving average is $30.16 and its 200-day moving average is $32.73. The company has a market cap of $1.412 billion and a price-to-earnings ratio of 85.31.

A number of research firms have recently commented on ACOR. Analysts at Zacks reiterated a “neutral” rating on shares of Acorda Therapeutics in a research note on Friday, January 17th. They now have a $32.00 price target on the stock. Analysts at Citigroup Inc. downgraded shares of Acorda Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, January 6th. They now have a $33.00 price target on the stock, down previously from $37.00. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $39.00.

Acorda Therapeutics, Inc (NASDAQ:ACOR) is a commercial-stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.